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these in terms of health care resource use and associated
costs, e.g., costs of hospitalisations, diagnostic and surgi-
cal procedures, outpatient care and drug consumption.
Panel and literature data was used for events not investi-
gated in the clinical trials. Cost inputs were derived from
Tampere University Hospital for year 1998. Days in re-
mission and relapse were translated into Quality Ad-
justed Life Years (QALYs) using CD specific health-state
utility data from the literature. RESULTS: The outcomes
of the clinical trials were reflected in the model as a
26.4% reduction in annual number of relapses for the av-
erage patient in the budesonide CIR treatment group.
Mean annual health care cost per patient was 17,740
FIM (2,000 USD) for the budesonide CIR patient and
16,608 FIM (1,877 USD) for the NMT patient. The dif-
ference between the groups amounted to a cost per
gained QALY of 68,610 FIM (7,753 USD), which is well
in line with what is considered a cost-effective treatment
strategy. CONCLUSION: Budesonide CIR means fewer
relapses per average patient and is a cost-effective treat-
ment strategy for the treatment of Crohn’s disease in Fin-
land.
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OBJECTIVES: Gastroesophageal reflux disease (GERD)
is a common condition associated with a variety of symp-
toms, particularly heartburn. The purpose of this study
was to assess patient-reported symptom distress in a ran-
domized trial of rabeprazole (RAB), a proton pump in-
hibitor. METHODS: Symptom distress was measured us-
ing the Distress subscale of the GERD Symptom Assessment
Scale (GSAS) that asks patients about the degree of
bother they experience for 15 symptoms. Patients com-
pleted the GSAS at baseline and week 4. We evaluated
the impact of treatment (RAB 10mg, RAB 20mg, or pla-
cebo) on mean change in GSAS Distress scores using an
ANCOVA model. We also conducted a relative variabil-
ity analysis using ANOVA models to determine which of
5 clinical indicators are most useful to explain changes in
GSAS Distress scores. Mean change was assessed as a
function of baseline daytime heartburn severity, baseline
nighttime heartburn severity, time to first 24 hours with-
out heartburn symptoms, complete daytime heartburn re-
lief, and complete nighttime heartburn relief. RESULTS:
The sample consisted of 169 patients (RAB10mg  55,
RAB 20mg  56, placebo  58). Overall, a significant
difference in mean change in GSAS Distress scores was
observed across treatment groups (p  0.0007). Both the
RAB 10mg and RAB 20mg groups reported significantly
greater improvements in GSAS Distress scores than the
placebo group (p  0.0036 and p  0.0004, respectively).
Of the 5 clinical indicators examined, time to first 24
hours without heartburn explained the greatest amount
of variability in GSAS Distress scores. Achieving com-
plete daytime and complete nighttime heartburn relief
also were significant factors. CONCLUSIONS: In clinical
studies, RAB provided fast and consistent (both daytime
and nighttime) heartburn relief. Given that speed of
heartburn relief as well as achieving complete heartburn
relief were significant factors explaining variability in pa-
tient-reported symptom distress, the positive impact of
RAB on the GSAS distress scale was consistent with its
clinical efficacy.
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OBJECTIVES: With recent recognition of the primary
role of Helicobacter pylori (HP) in peptic ulcer disease, it
has been proposed that patients with dyspepsia undergo
noninvasive testing for HP, instead of endoscopy, fol-
lowed by antibiotics if positive. We evaluated cost-effec-
tiveness of ‘Test&Treat’ strategy versus empirical treat-
ment for HP infection in dyspeptic patients presenting in
the primary care setting. METHODS: The study was a
one-year incremental cost (yr2000 US dollars) per qual-
ity-adjusted life year (QALY) model for dyspeptic pa-
tients age less than 45 years old in a primary care setting
from a societal perspective. With ‘Test&Treat’ algo-
rithm, patients were tested for HP infection using urea
breath test. If positive, eradication was prescribed. Alter-
natively, patients were given conventional treatment of
H2RA for four weeks. If not cured, HP would be eradi-
cated empirically. Both direct and indirect costs were in-
cluded. The model took into consideration preventing
gastric cancer from eradication. Sensitivity analyses were
performed on prevalence of HP infection, drug treatment
efficacy, laboratory test costs, drug treatment costs, and
drug treatment utility loss. RESULTS: At baseline, with
HP prevalence of 40% and HP antibiotic eradication effi-
cacy of 89%, results showed that ‘Test&Treat’ had an in-
cremental cost-effective ratio (ICER) of $31,723/QALY.
One-way sensitivity analysis showed that antibiotic treat-
ment efficacies lower than 45–46% would exceed the so-
cietal threshold ICER of $50,000. CONCLUSIONS: The
model showed that ‘Test&Treat’ was cost-effective for
uncomplicated dyspeptic patients in primary care. Al-
though NIH guidelines state that all ulcer patients with
HP infection require eradication regimen, universal endo-
scopic diagnosis of ulcer causation (HP/HP) would not
be cost-effective. However, treating all patients empirically
could increase antibiotic resistance. The ‘Test&Treat’
strategy has the benefits of slowing antibiotic resistance
while avoiding high endoscopy costs. The model was ro-
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bust to changes of most parameters—most sensitive to
prevalence and eradication efficacy changes.
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BACKGROUND: With a prevalence of up to 20%, Irri-
table Bowel Syndrome (IBS) could cost the German Sick-
ness Funds (GKV) more than DM 28 billion (10,5% of
its total expenditures) per year. Despite these potentially
tremendous costs it is still a fairly obscure disease in
terms of proper diagnosis and lacking effective treatment.
OBJECTIVE: To assess diagnosis and treatment options
of IBS using strict Rome-II criteria. METHODS: Face-to-
face interviews of patients (121) and physicians (147
GPs, 53 internists). RESULTS: The patient survey (age
14–74 yrs.; strict Rome-II criteria) puts the prevalence of
IBS (constipated and alternating type) in Germany at
around 2.3% (1.4 million). This figure correlates well
with previous findings. The patients responded that they
experienced an average of 7 episodes per year, each last-
ing about 4–5 days. Some 11% of them suffer perma-
nently. Of the physicians questioned, only 73% recognize
IBS when given the symptoms; 57% of these actually
classify it accordingly while an alternative diagnosis is
“irritable colon” (24%). When choosing a drug, daily
treatment costs outweigh every other factor of the physi-
cians relevant set (efficacy, onset, side-effects, mode of
action etc.) by about 3:1. In consequence a drug treat-
ment is initiated in (only) 40% of the cases. This is also
due to a lack of effective and specific treatment which
could help to reduce the frequency of episodes. Results of
another study put the direct costs of the average IBS pa-
tient at around DM 1,729 per year. Combining this with
the above findings results in a more realistic figure of
around DM 988 million in direct costs per year (0.37%
of total GKV expenditures). CONCLUSION: These com-
parably high costs (insulin treated diabetes: DM 1,217
p.a.) could be significantly reduced by DM 247 for each
episode prevented through proper diagnosis and conse-
quent treatment with a specific and effective medication.
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OBJECTIVES: The objective was to describe the disease
state (DS) transition patterns of gastroesophageal reflux
disease (GERD) by applying a multi-state model assum-
ing a Markov process. METHODS: This retrospective
study utilized administrative claims for subjects with
GERD from a large Midwest USA health care plan. Sub-
jects were tracked for six, six-month time periods (base-
line and five followups). Within each time period, ICD-9
diagnosis codes were used to categorize subjects’ GERD
into four DS plus a non-symptomatic state: DS0 {no
GERD diagnosis}, DS1 {mild esophagitis}, DS2 {reflux
esophagitis}, DS3 {esophageal ulceration}, and DS4 {stric-
tures and complications}. GERD transition probabilities
and patterns were analyzed in a five-state Markov frame-
work. Disease regressions and progressions were al-
lowed. The effects of patient and provider covariables on
transition probabilities were modeled using logistic re-
gression techniques. RESULTS: A total of 7575 subjects
with GERD were analyzed. In the five followup periods
combined, 79% of the subjects were in GERD DS0, 6%
in DS1, 8% in DS2, 2% in DS3, and 5% in DS4. For all
initial DS, the most frequent transition path was to re-
gress to DS0 (becoming non-symptomatic) and the sec-
ond most common was to stay in the initial disease state.
For subjects ending a time period in DS1, 89% regressed
to DS0 in the next time period, while 6% stayed in DS1,
3% progressed to DS2, 1% progressed to DS3, and 1%
progressed to DS4. Multivariate modeling of risk factors
influencing transitions showed that progressing from
DS1 is associated with age 70, a proton pump inhibitor
prescription, and absence of a diagnostic procedure.
CONCLUSIONS: The Markov analysis showed that sub-
jects with GERD commonly have their symptoms regress,
with only a small percent progressing. The Markov
model is a useful methodology to research disease states
in a retrospective database setting within a health care
plan.
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OBJECTIVES: Approximately one-half of the American
population experiences weekly symptoms of gastroesoph-
ageal reflux disease (GERD). With the hypothesis that
not all patients are completely symptom free on proton
pump inhibitor’s (PPI’s), the pharmaceutical industry is
formulating more potent anti-secretory drug therapies. In
November of 2000 the FDA approved esomeprazole for
the treatment of Erosive Esophagitis (EE). Esomeprazole
is a more potent inhibitor of gastrin and gastric acid,
with clinical studies demonstrating quicker symptom re-
lief with more complete 24-hour acid control. If complete
acid control translates into better long-term symptom re-
lief for chronic symptomatic GERD it may play a vital
